Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 20/20 | 1.00 |
| ▸ | POT1 | Q9NUX5 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30693401 | 0.99 | TERT (0.98) | TERTPOT1 | |
| Hydrochloric Acid SCHEMBL21980540 | 0.99 | TERT (0.98) | TERTPOT1 | |
| Hydrochloric Acid SCHEMBL30169726 | 0.99 | TERT (0.98) | TERTPOT1 | |
| SCHEMBL14355567 | 0.96 | TERT (1.00) | TERTPOT1 | |
| SCHEMBL31237519 | 0.95 | TERT (0.91) | TERTPOT1 | |
| SCHEMBL14355582 | 0.92 | TERT (1.00) | TERTPOT1 | |
| SCHEMBL14355607 | 0.90 | TERT (1.00) | TERTPOT1 | |
| SCHEMBL14355621 | 0.90 | TERT (1.00) | TERTPOT1 | |
| SCHEMBL13989201 | 0.89 | TERT (0.81) | TERTPOT1 | |
| SCHEMBL14355628 | 0.87 | TERT (1.00) | TERTPOT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281502-A1 | NEW DRUG APPLICATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-09-11 | — | — | US | claimed |
| WO-2024254465-A2 | METHODS FOR PROMOTING EXPANSION OF HUMAN CD34+ CELLS IN VIVO AND FOR PROMOTING NEURAL REGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-12 | — | — | WO | claimed |
| CN-118033105-A | Method for screening G-quadruplex ligand | 中国科学院化学研究所 | 2024-05-14 | — | — | CN | claimed |
| US-20240148688-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | UNIV CALIFORNIA (US) | 2024-05-09 | — | — | US | claimed |
| EP-4362943-A2 | NEW DRUG APPLICATION | Centre National de la Recherche Scientifique (FR) | 2024-05-08 | — | — | EP | claimed |
| US-20240108734-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | UNIV CALIFORNIA (US) | 2024-04-04 | — | — | US | claimed |
| WO-2023245207-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF CANINE CANCERS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2023-12-21 | — | — | WO | claimed |
| EP-4284519-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | The Regents of the University of California (US) | 2023-12-06 | — | — | EP | claimed |
| EP-4281560-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | The Regents of the University of California (US) | 2023-11-29 | — | — | EP | claimed |
| CN-116829142-A | Methods for treating and ameliorating cancer | 加利福尼亚大学董事会 | 2023-09-29 | — | — | CN | claimed |
| WO-2023275369-A2 | NEW DRUG APPLICATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-01-05 | — | — | WO | claimed |
| WO-2022165398-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | WO | claimed |
| US-12534499-B2 | Mesophilic argonaute systems and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-01-27 | — | — | US | disclosed |
| US-12442000-B2 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | GERON CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-12435055-B2 | 3-methylideneoxan-4-one compounds and substituted derivates thereof as inhibitors of telomerase | NORTHWESTERN UNIVERSITY (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250281502-A1 | NEW DRUG APPLICATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-09-11 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| WO-2006124904-A2 | CANCER TREATMENT BY COMBINED INHIBITION OF TELOMERASE AND HSP90 ACTIVITIES | GERON CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006113426-A2 | CANCER TREATMENT BY COMBINED INHIBITION OF TELOMERASE AND TUBULIN ACTIVITIES | GERON CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006113470-A2 | CANCER TREATMENT BY COMBINED INHIBITION OF PROTEASOME AND TELOMERASE ACTIVITIES | GERON CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534499-B2 | Mesophilic argonaute systems and uses thereof | RNASE1, AGO2, RNASEH1 | TERT 857/4885POT1 1063/4885 |
| US-12435055-B2 | 3-methylideneoxan-4-one compounds and substituted derivates thereof as inhibitors of telomerase | TERT, POT1, TERF2 | TERT 1/4885POT1 2/4885 |
| US-20240108734-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | FLT3, MCL1, ABL1 | TERT 38/4885POT1 1009/4885 |
| US-20240148688-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | ABL1, FLT3, MCL1 | TERT 20/4885POT1 446/4885 |
| US-12442000-B2 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | TERT, POT1, MPL | TERT 1/4885POT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.